[18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: A systematic review and meta-analysis

Cancer Imaging

Volumn 13, Issue 4, 2013, Pages 458-465

  Chien, Chun Ru ^a,b   Liang, Ji An ^a,b   Chen, Jin Hua ^c   Wang, Hsiao Nin ^a   Lin, Cheng Chieh ^a,b   Chen, Chih Yi ^a   Wang, Pin Hui ^a   Kao, Chia Hung ^a,b   Yeh, Jun Jun ^d,e,f  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Ditmanson Medical Foundation Chia Yi Christian Hospital   (Taiwan)

^e CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^f MEIHO UNIVERSITY   (Taiwan)

Author keywords

Cancer screening; Lung cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DESCRIPTIVE RESEARCH; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LOW DRUG DOSE; LUNG CANCER; META ANALYSIS; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EARLY DETECTION OF CANCER; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890208495     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0038     Document Type: Review

References (35)

1. NCCN clinical practice guidelines in oncology: Lung Cancer Screening 2013.v.1. Available from : http://www.nccn.org/professionals/physician-gls/pdf/ lung-screening.pdf (accessed 11 July 2012).
2. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409. doi: 10.1056/NEJMoa1102873. PMid: 21714641.
3. MacManus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys 2008; 72: 1298-1306. doi: 10.1016/j.ijrobp.2008.08.022. PMid: 19028270.
4. Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010; 5: 612-619. doi: 10.1097/JTO.0b013e3181d0a4f5. PMid: 20234323.
5. Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol 2009; 193: 1203-1211. doi: 10.2214/AJR.09.3193. PMid: 19843732.
6. Coche E, Lonneux M, Geets X. Lung cancer: morphological and functional approach to screening, staging and treatment planning. Future Oncol 2010; 6: 367-380. doi: 10.2217/fon.10.7. PMid: 20222794.
7. 18F- fluorodeoxyglucose uptake on positron emission tomography with ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. Eur J Radiol 2010; 75: e62-e66. doi: 10.1016/j.ejrad.2009.11.020. PMid: 20005653.
8. Chang CY, Chang SJ, Chang SC, Yuan MK. The value of positron emission tomography in early detection of lung cancer in high risk population: a systematic review. Clin Respir J 2013; 7: 1-6. doi: 10.1111/j.1752-699X.2012. 00290.x. PMid: 22404955.
9. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008; 246: 772-782. doi: 10.1148/radiol.2463062148. PMid: 18235105.
10. Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007; 48(Suppl 1): 4S-18S. doi: 10.2967/jnumed.107.044446. PMid: 17204716.
11. Black C, de Verteuil R, Walker S, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax 2007; 62: 131-138. doi: 10.1136/thx.2006.064659. PMid: 17287305.
12. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report. Ann Nucl Med 2008; 22: 379-385. doi: 10.1007/s12149-008-0130-7. PMid: 18600415.
13. 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med 2009; 23: 685-691. doi: 10.1007/s12149-009-0291-z. PMid: 19662344.
14. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536. doi: 10.1059/0003-4819-155-8-201110180-00009. PMid: 22007046.
15. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31. doi: 10.1186/1471-2288-6-31. PMid: 16836745.
16. Harbord RM, Whiting P. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009; 9: 211-229.
17. Chen YK, Ding HJ, Su CT, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res 2004; 24: 4103-4108. PMid: 15736459.
18. Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 2006; 50: 23-27. PMid: 16557201.
19. 18F- fluorodeoxyglucose positron emission tomography in cancer screening - a preliminary report. Oncol Rep 2001; 8: 1145-1148. PMid: 11496332.
20. Shibata K, Arai M, Matsuura M, et al. Relationship of detection rate of PET cancer screening examinees and risk factors: analysis of background of examinees. Ann Nucl Med 2011; 25: 261-267. doi: 10.1007/s12149-010-0458-7. PMid: 21188657.
21. 18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol 2009; 27: 1767-1773. doi: 10.1200/JCO.2008.18.2238. PMid: 19255324.
22. Ono K, Ochiai R, Yoshida T, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med 2007; 21: 65-72. doi: 10.1007/BF3034001. PMid: 17373338.
23. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005; 171: 1378-1383. doi: 10.1164/rccm.200411-1479OC. PMid: 15790860.
24. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003; 362: 593-597. doi: 10.1016/S0140-6736(03)14188-8. PMid: 12944057.
25. Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 2008; 61: 340-349. doi: 10.1016/j.lungcan.2008.01.001. PMid: 18308420.
26. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011; 66: 315-319. doi: 10.1136/thx.2010.136747. PMid: 21169285.
27. 18F-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial. J Thorac Oncol 2011; 6: 1704-1712. doi: 10.1097/JTO.0b013e3182286d0b. PMid: 21876458.
28. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012; 7: 10-19. doi: 10.1097/JTO.0b013e31823c58ab. PMid: 22173661.
29. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current American Cancer Society Guidelines and issues in cancer screening. CA Cancer J Clin 2011; 61: 8-30. doi: 10.3322/caac.20096. PMid: 21205832.
30. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011; 6: 1841-1848. doi: 10.1097/JTO.0b013e31822e59b3. PMid: 21892105.
31. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007; 297: 953-961. doi: 10.1001/jama.297.9.953. PMid: 17341709.
32. Infante M, Chiesa G, Solomon D, et al. Surgical procedures in the DANTE trial, a randomized study of lung cancer early detection with spiral computed tomography: comparative analysis in the screening and control arm. J Thorac Oncol 2011; 6: 327-335. doi: 10.1097/JTO.0b013e318200f523. PMid: 21178639.
33. Byrne MM, Koru-Sengul T, Zhao W, Weissfeld JL, Roberts MS. Healthcare use after screening for lung cancer. Cancer 2010; 116: 4793-4799. doi: 10.1002/cncr.25466. PMid: 20597136.
34. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010; 11: 75-84. doi: 10.1016/S1470-2045(09)70160-3. PMid: 20129130.
35. Deppen S, Putnam Jr JB, Andrade G, et al. Accuracy of FDGPET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg 2011; 92: 428-433. doi: 10.1016/j.athoracsur.2011.02.052. PMid: 21592456.